文献速递介入胸部DSACTPET

支气管或肺动脉化疗栓塞治疗不可切除且不可消融的肺转移瘤:一项I期临床试验

Bronchial or Pulmonary Artery Chemoembolization for Unresectable and Unablatable Lung Metastases: A Phase I Clinical Trial.
PubMed 文献 · Radiology · 2021-08-31

这项前瞻性单中心单臂I期临床试验纳入10例全身化疗失败的不可切除/不可消融肺、支气管内或纵隔转移瘤患者,经血管造影确定血供后行支气管或肺动脉化疗栓塞(碘化油+丝裂霉素乳剂后微球)。技术成功率为10/10(100%,95%CI 78-100),无严重不良事件(95%CI 0-22);4-6周碘化油滞留与肿瘤缩小及代谢活性降低相关。

要点

  • 肺转移瘤血供多来自支气管动脉(9/10),少数来自肺动脉(1/10),栓塞前需血管造影明确。
  • 化疗栓塞技术成功率高(100%),无严重不良事件,初步安全性可接受。
  • 4-6周碘化油滞留程度与肿瘤缩小和代谢活性降低相关,可作为早期疗效观察指标。

关键影像表现/征象

  • 9/10例(90%)肺转移瘤由支气管动脉供血,1/10例(10%)由肺动脉供血。
  • 4-6周碘化油滞留与肿瘤缩小相关(ρ = -0.83,P = .003),与代谢活性降低相关(ρ = -0.71,P = .03)。
  • 药代动力学显示丝裂霉素45%在2分钟内突释,55%滞留瘤内,半衰期超过5小时;初始肿瘤/血浆浓度比为380。

诊断标准与关键数值

  • 技术成功(瘤内给药)率为10/10(100%,95%CI:78,100)。
  • 无严重不良事件(95%CI:0,22)。
  • 按RECIST评估的缓解率为1/10(10%),按PERCIST评估的缓解率为4/10(40%)。

临床应用与阅片要点

  • 化疗栓塞前应行肺动脉和支气管动脉造影,明确转移瘤血供来源以选择栓塞靶血管。
  • 术后4-6周可观察碘化油滞留情况,滞留明显者可能预示肿瘤缩小和代谢活性降低。
  • 该治疗适用于全身化疗失败、不可切除且不可消融的肺转移瘤患者,需注意本组样本量小。

局限性

  • 单中心、单臂、样本量仅10例的I期临床试验,结果需更大样本验证。
  • 原文未报告长期随访的疗效和生存数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Lung chemoembolization is an emerging treatment option for lung tumors, but the optimal embolic, drug, and technique are unknown. Purpose To determine the technical success rate and safety of bronchial or pulmonary artery chemoembolization of lung metastases using ethiodized oil, mitomycin, and microspheres. Materials and Methods Patients with unresectable and unablatable lung, endobronchial, or mediastinal metastases, who failed systemic chemotherapy, were enrolled in this prospective, single-center, single-arm, phase I clinical trial (December 2019-September 2020). Pulmonary and bronchial angiography was performed to determine the blood supply to the lung metastases. Based on the angiographic findings, bronchial or pulmonary artery chemoembolization was performed using an ethiodized oil and mitomycin emulsion, followed by microspheres. The primary objectives were technical success rate and safety, according to the National Cancer Institute Common Terminology Criteria for Adverse Events. CIs of proportions were estimated with the equal-tailed Jeffreys prior interval, and correlations were evaluated with the Spearman test. Results Ten participants (median age, 60 years; interquartile range, 52-70 years; six women) were evaluated. Nine of the 10 participants (90%) had lung metastases supplied by the bronchial artery, and one of the 10 participants (10%) had lung metastases supplied by the pulmonary artery. The technical success rate of intratumoral drug delivery was 10 of 10 (100%) (95% CI: 78, 100). There were no severe adverse events (95% CI: 0, 22). The response rate of treated tumors was one of 10 (10%) according to the Response Evaluation Criteria in Solid Tumors and four of 10 (40%) according to the PET Response Criteria in Solid Tumors. Ethiodized oil retention at 4-6 weeks was correlated with reduced tumor size (ρ = -0.83, P = .003) and metabolic activity (ρ = -0.71, P = .03). Pharmacokinetics showed that 45% of the mitomycin dose underwent burst release in 2 minutes, and 55% of the dose was retained intratumorally with a half-life of more than 5 hours. The initial tumor-to-plasma ratio of mitomycin concentration was 380. Conclusion Lung chemoembolization was technically successful for the treatment of lung, mediastinal, and endobronchial metastases, with no severe adverse events. Clinical trial registration no. NCT04200417 © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Georgiades et al in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Boas FE, Kemeny NE, Sofocleous CT, et al. Bronchial or Pulmonary Artery Chemoembolization for Unresectable and Unablatable Lung Metastases: A Phase I Clinical Trial. Radiology. 2021. PMID: 34463550. doi:10.1148/radiol.2021210213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。